Tesorai Raises $5.3M Seed Round Backed by Perplexity Fund and IQT

Tesorai Raises $5.3M Seed Round Backed by Perplexity Fund and IQT
North AmericaFunding
WorkNation
November 19, 2026

Tesorai, a San Diego-based AI startup focused on making raw scientific experimental data searchable, has raised $5.3 million in a seed funding round backed by Perplexity Fund, IQT and South Central Ventures, alongside five other investors. The round brings the company's total funding to $8 million.

The company is developing AI infrastructure that extracts insights from raw laboratory data, helping researchers access findings that may remain buried in experiments, public repositories and institutional archives.

Tesorai plans to use the new capital to expand its work with biopharmaceutical and research organisations, establish partnerships across the life sciences tools industry, and extend its platform beyond proteins to other types of molecular data.

Founded by former Verily colleagues Melissa Miao, Peter Cimermancic and Charlie Kim, the company is targeting a data accessibility problem in scientific research: experiments often generate substantially more information than is ultimately reported in published papers.

Making Raw Experimental Data Searchable

Scientific experiments produce large volumes of data, but accessing and comparing results across studies can be difficult. Data is distributed across public repositories, institutional archives and private company databases, often stored in different formats and processed using different methods.

Tesorai's platform works directly with underlying experimental data rather than relying only on published papers or previously generated analyses. Its AI processes and harmonises results across experiments, making them searchable and allowing researchers to investigate what the original experiments reveal.

The company currently offers three products:

  • Tesorai Search: Processes raw mass spectrometry data from both new and historical studies. The product has been peer-reviewed in the Journal of Molecular Biology.

  • Tesorai Chat: Enables researchers to run downstream analyses using conversational prompts, including workflows that would typically require bioinformatics expertise. It can also be accessed through a connector to large language models.

  • Tesorai Trove: Provides an AI-ready catalogue of curated public proteomics datasets that researchers can use to validate and compare their own findings.

According to the company, its patented model has processed thousands of files and terabytes of data within a few hours, compared with workflows that previously took months.

Recovering an Alzheimer’s Marker From Earlier Studies

One example highlighted by Tesorai involved reprocessing raw data from five publicly available brain studies.

The company says its platform recovered p-tau217, a protein associated with Alzheimer's disease, from those datasets. The marker was among seven proteins included in an Alzheimer's panel published in JAMA Neurology on August 10.

The example illustrates the potential value of revisiting existing experimental data. Information that was not identified or reported in an earlier analysis may still be present in the original files and could become accessible through new processing methods.

Tesorai is also exploring how its processed protein data could support the development of AI models of biology. In an August preprint, the company's researchers reported that adding protein data enabled a small single-cell model to match or outperform larger models trained only on RNA data across multiple benchmarks. One of the models was more than 40 times its size.

Founders Bring Experience From Verily

Tesorai was founded by Melissa Miao, Peter Cimermancic and Charlie Kim, who previously worked together at Verily, Alphabet's life sciences company.

Miao led business initiatives and strategic partnerships at Verily and now serves as Tesorai's CEO. Cimermancic, the company's CTO, previously led AI teams, while Kim, its chief scientific officer, launched and led Verily's Molecular Science programme.

Since its pre-seed funding round, Tesorai says it has signed contracts with biopharmaceutical and research organisations. It has also collaborated with MD Anderson Cancer Center, NYU and the Michael J. Fox Foundation, and received its first US patent for one of its AI models.

The company's strategy is to make experimental data more useful not only for individual research teams, but also for organisations developing AI systems for biological research.

Eight Investors Back the Seed Round

The $5.3 million seed round includes participation from eight investors: Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures and ZAKA.

Investors see access to high-quality experimental data as an important factor in advancing AI-driven scientific research. Perplexity Fund co-founder and general partner Joanna Lee Shevelenko said the infrastructure Tesorai is building could help make scientific data more usable at scale.

South Central Ventures managing partner Tatjana Zabasu Mikuž also highlighted the growing volume of experimental data generated by laboratories and the need to process it efficiently.

Expanding Beyond Proteomics

With the new funding, Tesorai intends to broaden its customer base across biopharmaceutical and research organisations while developing partnerships with companies in the life sciences tools sector.

The company also plans to move beyond protein-focused datasets towards additional forms of molecular data. This could expand the range of experimental information researchers can search, compare and use in AI-driven workflows.

While much of the investment in AI for biology has focused on developing increasingly capable models, Tesorai is pursuing a complementary approach: improving access to the experimental evidence those models depend on.

Its next phase will test whether making previously difficult-to-access laboratory data searchable can help researchers extract more value from existing experiments and support the development of better AI systems for biology.

Press Release

Have a Funding Round or Exciting Update to Share?

Submit your press release to get featured on WorkNation and reach founders, investors, and tech leaders.